Some data are of total importance to all when a drug is known to exist factors that always create doubts about the population.
Eduardo Najar
Agencia Latina de Noticias Medicina y Salud Pública
Before the good news of the month of November, the pharmaceutical companies Pfizer and BioNTech announced that their vacancy would be met by all those requiring efficacy and security in order for pudiese to be administered in the population and to end one of the pandemics. Geen hindernis, al dya de hoy se desconocen algunos datos o factors om los que lablancion debería tener acceso y conocer.
Many of them have questions about manufacturing and secondary effects, administration and demas that surge from the new drugs, are some points of this vacancy that the population should know:
Scientific discovery
To initiate the immunization process the companies will determine their population and a method of administering the vaccine and the other method of injecting a placebo, the methodology that can be used to ensure that the people who are involved and how they behave the effectiveness of the drug. This form can determine that 94 people out of 44,000 who have had positive outcomes to COVID, are now accounted for by individuals directly receiving the drug and the placebo and can determine that the efficacy exceeds 90% of functionality.
Vaccine Administration and Protocols
It has been determined by multiple types of market entities and recommendations of international institutions such as the OMS that the first dose of the vaccine should have a restricted administration protocol with the end of which it has control.
The first people to receive the vaccine are their professional health care providers who are located in the first line of attention to COVID patients and will be able to receive their services and acquaintances to help with this pandemic.
At the same time, priority is being given to this potentially chronic population, which has some pathogens that can complicate a diagnosis and include risky living, in addition to the most vulnerable people and economically scarce resources.
Public availability in general
The accessibility depends on whether the various protocols are determined in national territory, and then some priorities are determined in certain determinations, the access being as soon as possible and one of the persons can be evacuated without any limitation.
Public offering
According to preliminary studies, it is possible that the adult population will be protected by the vaccine, without embarrassment, claiming that these individuals have a minor rank in the assessment of their immune system. Pfizer has announced that it will continue its study and amplify it individuals.
Children and peoples more pequeña
The studies that have been performed on some 18-year-olds have been validated, without embarrassment, and are currently undergoing clinical trials for adolescents and children of temporary age.